Anixa Biosciences (NASDAQ:ANIX) Stock Price Down 0.4%

Anixa Biosciences, Inc. (NASDAQ:ANIX)’s stock price dropped 0.4% during mid-day trading on Wednesday . The stock traded as low as $2.26 and last traded at $2.26. Approximately 12,534 shares changed hands during mid-day trading, a decline of 89% from the average daily volume of 118,743 shares. The stock had previously closed at $2.27.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright cut their target price on shares of Anixa Biosciences from $12.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, June 10th.

Anixa Biosciences Stock Down 0.4 %

The firm’s 50-day simple moving average is $2.67 and its 200-day simple moving average is $3.41. The firm has a market capitalization of $72.34 million, a PE ratio of -6.11 and a beta of 0.89.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings results on Tuesday, June 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. On average, equities research analysts forecast that Anixa Biosciences, Inc. will post -0.43 earnings per share for the current year.

Insider Buying and Selling at Anixa Biosciences

In other Anixa Biosciences news, Director Lewis H. Titterton, Jr. purchased 15,009 shares of the business’s stock in a transaction on Tuesday, April 9th. The stock was acquired at an average cost of $3.28 per share, for a total transaction of $49,229.52. Following the completion of the transaction, the director now directly owns 838,037 shares in the company, valued at approximately $2,748,761.36. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, Director Lewis H. Titterton, Jr. bought 15,009 shares of the company’s stock in a transaction dated Tuesday, April 9th. The stock was bought at an average cost of $3.28 per share, for a total transaction of $49,229.52. Following the completion of the acquisition, the director now owns 838,037 shares in the company, valued at approximately $2,748,761.36. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Lewis H. Titterton, Jr. bought 10,738 shares of the company’s stock in a transaction dated Friday, June 7th. The shares were purchased at an average price of $2.52 per share, with a total value of $27,059.76. Following the completion of the acquisition, the director now owns 848,775 shares of the company’s stock, valued at approximately $2,138,913. The disclosure for this purchase can be found here. Insiders acquired a total of 57,732 shares of company stock worth $153,491 over the last three months. Company insiders own 22.60% of the company’s stock.

Institutional Trading of Anixa Biosciences

Institutional investors have recently modified their holdings of the company. Staley Capital Advisers Inc. purchased a new stake in shares of Anixa Biosciences during the first quarter worth about $31,000. Simplicity Wealth LLC bought a new position in Anixa Biosciences in the first quarter worth about $44,000. Virtu Financial LLC raised its stake in Anixa Biosciences by 47.2% in the first quarter. Virtu Financial LLC now owns 16,156 shares of the company’s stock worth $50,000 after buying an additional 5,183 shares in the last quarter. Finally, International Assets Investment Management LLC raised its stake in Anixa Biosciences by 274.6% in the fourth quarter. International Assets Investment Management LLC now owns 54,320 shares of the company’s stock worth $2,110,000 after buying an additional 39,820 shares in the last quarter. 29.13% of the stock is currently owned by hedge funds and other institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.